Sponsor:
Aeovian Pharmaceuticals, Inc.
Code:
NCT07680322
Conditions
Tuberous Sclerosis Complex
Epilepsy
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
AV078
Placebo
Brief summary:
Conditions
Tuberous Sclerosis Complex
Epilepsy
Study ID
NCT07680322
Start date
Oct 5, 2026
Status verified date
Oct, 2026
Completion date
Dec 21, 2027
Anticipated
Primary completion date
Sep 1, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Enrollment
42 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: AV078
placebo comparator: Placebo
Interventions
AV078
Placebo
Primary outcome measure
Central contacts
Locations
London Health Sciences Centre
Recruiting
London, Ontario, Canada, N6A 5A5
Contacts
Principal Investigator:
Andrew House, MD
Sponsor
Aeovian Pharmaceuticals, Inc.
Last update posted
Nov 20, 2026
Last verified
Oct, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Aeovian Pharmaceuticals, Inc. on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.